期刊文献+

洛索洛芬钠速释缓释双层片药动学及其体内外相关性研究 被引量:3

Pharmacokinetics of double-layer tablets of Loxoprofen in rabbits
下载PDF
导出
摘要 目的建立家兔血浆中洛索洛芬钠浓度的HPLC定量分析方法,测定其在家兔体内的血药浓度经时过程,评价速释缓释双层片和普通片剂的生物等效性。方法血浆中加入内标布洛芬,酸化后经乙酸乙酯5mL提取,进行HPLC测定。给药方案采用单剂量自身交叉,采用DAS软件拟合药物浓度-时间曲线,计算药代动力学参数。结果与普通片相比,速释缓释双层片的tmax,t1/2,cmax降低,相对生物利用度为(105.74%±7.67)%。结论本方法专属性强,灵敏度高,准确性好。速释缓释双层片与普通片生物等效,具有明显的缓释特征。 OBJECTIVE To establish an HPLC method for the bioavailability and pharmacokinefics study of loxoprofen in rabbits. METHODS After adding ibuprofen(internal standard)and 1 mol·L^-1 HCL 100μL, 1 mL of plasma were extracted with 5mL of ethyl acetate and determined by HPLC. A randomized two-way crossover design was adopted. The parameters of pharmacokinetic were calculated by DAS program. RESULTS The results indicated that the tin= and the t1/2 of double-layer tablets(ER) were longer than those of immediate-release tablets (IR), and the cmax of ER was lower than that of IR: The bioavailability of ER relative to IR Was (105.74 ± 7.67) % .CONCLUSION The method was proved to be simple, sensitive and rapid.The two formulations had the same absorption extent. Comparing with IR, the ER exhibited good extended release tendency.
作者 张爱琴
出处 《海峡药学》 2011年第7期42-44,共3页 Strait Pharmaceutical Journal
关键词 洛索洛芬钠 HPLC 药代动力学 生物利用度 Loxoprofen HPLC Pharmacokinetics Bioavailability
  • 相关文献

参考文献2

二级参考文献10

  • 1[1]Choo KS, Kim IW, Jung JK, et al. Simultaneous determination of loxoprofen and its diastereomeric alcohol metabolites in human plasma and urine by a simple HPLC-UV detection method. J Pharm Biomed Anal, 2001; 25:639~650.
  • 2[2]Kim IW, Choo KS, Han TG, et al. Decreased oral bioavailability of loxoprofen at second administration in human subjects. Int J Clin Pharmacol Ther, 2000; 38:10~14.
  • 3[3]Hirai T, Matsumoto S, Kishi I. Imultaneous analysis of several non-steroidal anti-inflammatory drugs in human urine by highperformance liquid chromatography with normal solid-phase extraction. J Chromatogr B Biomed Sci Appl , 1997; 692:375~388.
  • 4Van der LS,Valkenburg H,Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria[J]. Arthritis Rheum, 1984,27: 361-368.
  • 5Anderson J, Baron G, van der Heijde D, et al. ASAS preliminary criteria for short term improvement in ankylosing spondylitis[J].Arthritis Rheum ,2001,44:1876-1886.
  • 6Calin A,Garrett S,Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index(BASFI)[J].J Rheumatol, 1994,21:2281-2285.
  • 7Garrett S, J enkinson T, Whitelock H, et al. A new approach to defining disease status in AS:the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)[J].J Rheumatol, 1994,21: 2286-2291.
  • 8Yanagawa A,Fukumura T,Matsui H, et al. Possible Mechanisms of gastroduodenal mucosal damage in volunteers Treated with NSAIDs: The usefulness of prodrugs[J].J Rheumatol, 1992,19:1075-1082.
  • 9李胜光,崔鸿雁,郭军华,杨春花,黄烽.洛索洛芬治疗膝骨关节炎的临床评价[J].中国新药杂志,2000,9(12):856-858. 被引量:15
  • 10赵伟,黄烽.强直性脊柱炎治疗新进展[J].中国新药杂志,2001,10(7):485-488. 被引量:19

共引文献21

同被引文献24

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部